Eli Lilly and Co
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle
Smith Collection | Archive Photos | Getty Images Obesity drug developer Metsera said on Friday that it had accepted Pfizer‘s $10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that erupted over the last week. Pfizer had appeared to have […]
Read More
Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. 6, 2025. Andrew Caballero-Reynolds | AFP | Getty Images President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in how many people can access […]
Read More
Musk’s $1 trillion pay, a price cut for obesity drugs, Target’s in-store woes and more in Morning Squawk
Tesla CEO Elon Musk attends the Saudi-U.S. Investment Forum, in Riyadh, Saudi Arabia, May 13, 2025. Hamad I Mohammed | Reuters This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading day: 1. +$1 trillion The richest man in […]
Read More
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows
The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows […]
Read More
Here’s how much weight loss drugs could cost you under Trump’s deals with Eli Lilly, Novo Nordisk
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and […]
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]
Read More
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients […]
Read More
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Metsera on Tuesday said Novo Nordisk‘s new […]
Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]
Read More
November trading, Berkshire’s cash hoard, Big Tech’s ad revenue and more in Morning Squawk
A trader works on the floor of the New York Stock Exchange on Oct. 30, 2025 in New York. Angela Weiss | AFP | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading day: 1. November […]
Read More